[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE473010T1 - Enzyme für pharmazeutische anwendung - Google Patents

Enzyme für pharmazeutische anwendung

Info

Publication number
ATE473010T1
ATE473010T1 AT05744343T AT05744343T ATE473010T1 AT E473010 T1 ATE473010 T1 AT E473010T1 AT 05744343 T AT05744343 T AT 05744343T AT 05744343 T AT05744343 T AT 05744343T AT E473010 T1 ATE473010 T1 AT E473010T1
Authority
AT
Austria
Prior art keywords
pharmaceutical use
enzymes
diabetes type
nocardiopsis
nrrl
Prior art date
Application number
AT05744343T
Other languages
English (en)
Inventor
Allan Svendsen
Svend Kaasgaard
Kim Borch
Morten Fischer
Dan Pettersson
Peter Gregory
Original Assignee
Novozymes As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes As filed Critical Novozymes As
Application granted granted Critical
Publication of ATE473010T1 publication Critical patent/ATE473010T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT05744343T 2004-05-24 2005-05-24 Enzyme für pharmazeutische anwendung ATE473010T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200400810 2004-05-24
DKPA200500101 2005-01-20
PCT/DK2005/000342 WO2005115445A1 (en) 2004-05-24 2005-05-24 Enzymes for pharmaceutical use

Publications (1)

Publication Number Publication Date
ATE473010T1 true ATE473010T1 (de) 2010-07-15

Family

ID=34968404

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05744343T ATE473010T1 (de) 2004-05-24 2005-05-24 Enzyme für pharmazeutische anwendung

Country Status (12)

Country Link
US (2) US20110158976A1 (de)
EP (1) EP1755656B1 (de)
JP (1) JP2008500055A (de)
AT (1) ATE473010T1 (de)
AU (1) AU2005247061A1 (de)
BR (1) BRPI0510817A (de)
CA (1) CA2586222A1 (de)
DE (1) DE602005022187D1 (de)
DK (1) DK1755656T3 (de)
MX (1) MXPA06013239A (de)
RU (1) RU2389504C2 (de)
WO (1) WO2005115445A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
CN1867668A (zh) 2003-10-10 2006-11-22 诺维信公司 蛋白酶变体
ATE541034T1 (de) * 2004-06-21 2012-01-15 Novozymes As Nocardiopsis-proteasen
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
WO2009071550A1 (en) * 2007-12-04 2009-06-11 Novozymes A/S Protease variants for pharmaceutical use
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
ATE539150T1 (de) * 2008-06-03 2012-01-15 Novozymes As Verfahren zur herstellung eines caseinhydrolysats
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
AU2015252099B2 (en) * 2009-01-06 2017-08-10 Galenagen, Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
NZ593823A (en) 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or the prevention of infections by e. coli
NZ593831A (en) * 2009-01-06 2013-09-27 Curelon Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011000924A1 (en) 2009-07-03 2011-01-06 Abbott Products Gmbh Spray-dried amylase, pharmaceutical preparations comprising the same and use
US8784884B2 (en) * 2009-09-17 2014-07-22 Stephen Perrett Pancreatic enzyme compositions and methods for treating pancreatitis and pancreatic insufficiency
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
GB2503852B (en) 2011-04-21 2018-12-12 Curemark Llc Compounds for the treatment of neuropsychiatric disorders
BR112013032861A2 (pt) 2011-07-22 2017-01-24 Novozymes North America Inc métodos para aumentar a atividade da enzima celulolítica durante a hidrólise do material celulósico, para hidrolisar um material celulósico pré-tratado, para a produção de um produto da fermentação, e para a fermentação de um material celulósico pré-tratado
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
DK2914611T3 (en) 2012-11-01 2018-12-10 Novozymes As Method of DNA Removal
EP2910129A1 (de) * 2014-02-21 2015-08-26 Clariant Produkte (Deutschland) GmbH Zusammensetzung für die enzymatische Ölentschleimung
JP6607409B2 (ja) * 2017-03-31 2019-11-20 株式会社東洋新薬 経口用組成物
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
WO2023225459A2 (en) 2022-05-14 2023-11-23 Novozymes A/S Compositions and methods for preventing, treating, supressing and/or eliminating phytopathogenic infestations and infections

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK564086A (da) 1986-11-25 1988-06-17 Novo Industri As Enzymatisk detergent-additiv
DK173590D0 (da) * 1990-06-06 1990-07-19 Novo Nordisk As Rekombinante terapeutiske lipaser
US5614224A (en) * 1995-04-20 1997-03-25 Womack; Rick W. Nutritional supplement for diabetics
US6051220A (en) * 1995-05-31 2000-04-18 Medzyme N.V. And Simon Lodewijk Scharpe Composition to improve digestibility and utilization of nutrients
FR2747045B1 (fr) * 1996-04-05 1998-06-26 Hooreman Michel Nouveau medicament optimisant la viscosite des mucus et ameliorant le fonctionnement de l'intestin
RU2268065C2 (ru) * 1999-03-17 2006-01-20 Зольвай Фармасьютиклз Гмбх Лекарственное средство, предназначенное для лечения диабета
CN1293191C (zh) * 2000-02-08 2007-01-03 Dsmip资产公司 酸－稳定性枯草蛋白酶在动物饲料中的用途
AR032392A1 (es) 2001-01-19 2003-11-05 Solvay Pharm Gmbh Mezcla de enzimas, preparado farmaceutico y utilizacion de dicho preparado.
AU2003250830A1 (en) * 2002-06-12 2003-12-31 Bayer Healthcare Ag Regulation of human subtilase-like serine protease
ES2315666T5 (es) 2003-06-19 2012-12-26 Novozymes A/S Proteasas
DE602004026446D1 (de) 2003-06-19 2010-05-20 Novozymes As Verbesserte proteasen und verfahren zu ihrer herstellung
WO2004111222A1 (en) 2003-06-19 2004-12-23 Novozymes A/S Proteases
CN1867668A (zh) 2003-10-10 2006-11-22 诺维信公司 蛋白酶变体

Also Published As

Publication number Publication date
JP2008500055A (ja) 2008-01-10
AU2005247061A1 (en) 2005-12-08
US20110158976A1 (en) 2011-06-30
DK1755656T3 (da) 2010-10-04
EP1755656B1 (de) 2010-07-07
DE602005022187D1 (de) 2010-08-19
CA2586222A1 (en) 2005-12-08
RU2006145899A (ru) 2008-06-27
WO2005115445A1 (en) 2005-12-08
US20120207741A1 (en) 2012-08-16
EP1755656A1 (de) 2007-02-28
RU2389504C2 (ru) 2010-05-20
BRPI0510817A (pt) 2007-11-20
MXPA06013239A (es) 2007-02-28

Similar Documents

Publication Publication Date Title
ATE473010T1 (de) Enzyme für pharmazeutische anwendung
MX2007015474A (es) Proteasas para uso farmaceutico.
MX2007015471A (es) Amilasas para uso farmaceutico.
TW200738256A (en) Lipases for pharmaceutical use
HUP0500560A2 (hu) Mikróbás enzimek új keverékei
MX2009006597A (es) Variantes de lipasa para uso farmaceutico.
WO2005111203A3 (en) MUTANT α ΑMYLASES
JP2008521906A5 (de)
TR200102784T2 (tr) Diyabet tedavisi için ilaç
NZ596269A (en) Protease screening methods and proteases identified thereby
WO2007053619A3 (en) A composition with a fungal (yeast) lipase and method for treating lipid malabsorption in cystic fibrous as well as people suffering from pancreatic lipase insufficiency
MX2010005690A (es) Variantes de proteasa para uso farmaceutico.
NO20065195L (no) Terapeutiske enzymformuleringer og anvendelser derav
MXPA02002901A (es) Enzimas de ruta de enfocado lisosomal.
WO2008021987A3 (en) Proteolytic enzyme formulations
WO2001097829A3 (en) Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
NZ595193A (en) Modified Proteases That Inhibit Complement Activation
IL209979A (en) Use of 70 hsp to prepare a drug to treat lysosomal storage disease
WO2003086452A3 (en) Methods of enhancing lysosomal storage disease therapy
EP1463512A4 (de) Verwendung von p97 als enzym-abgabesystem zur abgabe von therapeutischen lysosomalen enzymen
JP2002539173A5 (de)
AU2001292843A1 (en) Crystal structure of bace and uses thereof
ATE295737T1 (de) Verwendung von aus ciliaten gewonnenen enzymen als verdauungsfördernde arzneimittel
WO2005112987A3 (en) Method of preparation and use of fibrinolytic enzymes in the treatment of disease
Skidgel Characterization of the metabolism of substance P and neurotensin by human angiotensin I converting enzyme and" enkephalinase".

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties